title: Acceleration of partial-thickness burn wound healing with topical application of heparin-binding EGF-like growth factor (HB-EGF).
abstract: Heparin-binding EGF-like growth factor has been identified in human burn-wound fluid and in the epithelial cells of excised human partial-thickness burns. In the present study, the effect of heparin-binding EGF-like growth factor on burn-wound healing was evaluated by incorporating purified, recombinant heparin-binding EGF-like growth factor into slow-release cholesterol-lecithin pellets that were applied topically to partial-thickness burns in mice. Both experimental (heparin-binding EGF-like growth factor-treated) and control (untreated) mice were sacrificed on days 3, 5, and 10 after burn. Total burn-wound area, histology, keratinocyte proliferation, and in situ hybridization analysis for transforming growth factor-alpha were determined for each wound. The mean wound area of the experimental group on day 5 after burn was 1.07 cm2, compared with 2.20 cm2 for controls (p=0.04). Cellular proliferation (as measured by immunohistochemical detection of 5-Bromo-2-deoxyuridine) on day 5 after burn in marginal keratinocytes and follicular epithelial cells was greater in the experimental group than in the control group. In situ hybridization showed up-regulation of transforming growth factor-alpha mRNA levels in experimental animals by day 5 after burn. Topical application of heparin-binding EGF-like growth factor significantly accelerates the reepithelialization of murine partial-thickness burns, increases keratinocyte proliferative activity, and enhances production of endogenous transforming growth factor-alpha mRNA.
authors.affiliation: Department of Surgery, The Ohio State University and Columbus Children's Hospital, 43205, USA.
authors.forename: R K
authors.initials: RK
authors.lastname: Cribbs
authors.forename: M H
authors.initials: MH
authors.lastname: Luquette
authors.forename: G E
authors.initials: GE
authors.lastname: Besner
mesh_terms: D000287:Administration, Topical; D000818:Animals; D002056:Burns / Q000188:drug therapy* / Q000473:pathology; D002455:Cell Division; D004815:Epidermal Growth Factor / Q000008:administration & dosage / Q000494:pharmacology*; D004847:Epithelial Cells; D066257:Heparin-binding EGF-like Growth Factor; D036341:Intercellular Signaling Peptides and Proteins; D015603:Keratinocytes; D008297:Male; D051379:Mice; D012333:RNA, Messenger / Q000096:biosynthesis; D016211:Transforming Growth Factor alpha / Q000096:biosynthesis; D014945:Wound Healing
chemical_list: C587883:HBEGF protein, human; C587884:Hbegf protein, mouse; D066257:Heparin-binding EGF-like Growth Factor; D036341:Intercellular Signaling Peptides and Proteins; D012333:RNA, Messenger; D016211:Transforming Growth Factor alpha; D004815:Epidermal Growth Factor